Obstructive Sleep Apnea Hypopnea: Symptoms, Causes, Diagnosis, and Treatment

Obstructive sleep apnea hypopnea (OSAH) is a sleep-related breathing disorder characterized by repeated episodes of complete or partial upper airway obstruction during sleep. These episodes result in apneas — complete cessation of airflow for at least 10 seconds — and hypopneas — partial reductions in airflow that lead to decreased blood oxygen levels or brief awakenings from sleep (called arousals). The combined frequency of these events is measured using the apnea-hypopnea index (AHI), which counts the average number of apneas and hypopneas per hour of sleep.

During an obstructive event, the muscles of the throat relax excessively and the soft tissues of the upper airway collapse inward, physically blocking the passage of air despite the person's continued effort to breathe. The brain detects the resulting drop in oxygen or rise in carbon dioxide and triggers a brief arousal — often so short the person has no memory of it — to restore muscle tone and reopen the airway. This cycle can repeat dozens or even hundreds of times per night, profoundly fragmenting sleep architecture and preventing restorative deep sleep and REM sleep.

The DSM-5-TR classifies obstructive sleep apnea hypopnea under Sleep-Wake Disorders and requires evidence from polysomnography of at least five obstructive apneas or hypopneas per hour of sleep accompanied by typical nocturnal breathing symptoms or daytime sleepiness, or evidence of 15 or more obstructive apneas and/or hypopneas per hour regardless of accompanying symptoms. Severity is specified as mild (AHI 5–14), moderate (AHI 15–29), or severe (AHI ≥30).

OSAH is remarkably common. According to estimates from the National Institutes of Health and large epidemiological studies, clinically significant obstructive sleep apnea affects approximately 10–30% of adults, with prevalence increasing substantially with age and body mass index. Among middle-aged adults, research consistently finds rates of approximately 13–14% in men and 5–6% in women. However, the condition is widely underdiagnosed — studies suggest that up to 80% of moderate-to-severe cases remain unidentified in the general population.

The symptoms of obstructive sleep apnea hypopnea span both nighttime and daytime functioning. Because the person experiencing apneic events is typically asleep, bed partners are often the first to notice key warning signs.

Nighttime symptoms include:

• Loud, chronic snoring — often with a crescendo pattern that intensifies before an apneic episode, followed by silence and then a gasping or choking sound as breathing resumes
• Witnessed apneas — a bed partner observes the person stop breathing, sometimes for alarming durations
• Gasping, choking, or snorting during sleep
• Restless sleep — frequent position changes, thrashing, or kicking
• Nocturia — waking multiple times to urinate, driven by pressure changes in the heart during apneic events that increase urine production
• Night sweats unrelated to room temperature
• Dry mouth or sore throat upon waking, often from mouth breathing

Daytime symptoms include:

• Excessive daytime sleepiness (EDS) — the hallmark complaint, ranging from mild drowsiness to falling asleep involuntarily during conversations, meals, or while driving
• Morning headaches — typically bilateral, dull, and pressing, resolving within a few hours of waking
• Cognitive impairment — difficulties with attention, concentration, working memory, and executive function
• Mood disturbances — irritability, emotional lability, depressive symptoms, and anxiety
• Decreased libido and sexual dysfunction
• Fatigue and low energy that persists despite apparently adequate time in bed

Notably, not all individuals with OSAH snore loudly, and not all loud snorers have sleep apnea. Some individuals — particularly women and older adults — present with atypical symptoms such as insomnia, fragmented sleep, morning fatigue without obvious sleepiness, or mood and cognitive complaints as the primary concern. This contributes to underdiagnosis, especially in populations that do not fit the stereotypical profile of a middle-aged, overweight male who snores.

Obstructive sleep apnea hypopnea arises from a combination of anatomical and physiological factors that compromise the patency (openness) of the upper airway during sleep.

Anatomical risk factors:

• Obesity — the single strongest modifiable risk factor. Fat deposition around the pharynx, tongue, and soft palate narrows the upper airway. A 10% increase in body weight is associated with approximately a six-fold increase in the risk of developing moderate-to-severe OSAH.
• Craniofacial structure — a retrognathic mandible (receding jaw), a small or narrow maxilla, a large tongue (macroglossia), enlarged tonsils or adenoids, a thick soft palate, or a low-lying hyoid bone all reduce airway caliber.
• Neck circumference — neck circumferences greater than 17 inches in men and 16 inches in women are associated with elevated risk.
• Nasal obstruction — a deviated septum, nasal polyps, or chronic nasal congestion increase negative inspiratory pressure demands and destabilize the airway.

Physiological and neuromuscular factors:

• Reduced upper airway dilator muscle tone — during sleep, particularly during REM sleep, the genioglossus and other pharyngeal muscles lose tone, allowing the airway to narrow or collapse.
• Ventilatory control instability (high loop gain) — in some individuals, the brain's respiratory control system overreacts to small changes in blood gases, leading to oscillations in respiratory drive that promote apneic events.
• Low arousal threshold — individuals who wake too easily from sleep may arouse before airway-stabilizing compensatory mechanisms can take effect, perpetuating respiratory instability.

Demographic and behavioral risk factors:

• Age — prevalence increases progressively through middle age and older adulthood
• Sex — males are approximately two to three times more likely than females to have OSAH, though this gap narrows after menopause
• Menopause — declining estrogen and progesterone levels appear to reduce upper airway muscle tone and alter fat distribution, increasing risk in postmenopausal women
• Family history — genetic factors account for an estimated 40% of AHI variance, reflecting heritable craniofacial anatomy, body fat distribution, and ventilatory control characteristics
• Alcohol and sedative use — these substances relax pharyngeal muscles, worsen airway collapsibility, and blunt the arousal response
• Smoking — associated with upper airway inflammation and fluid retention that narrows the airway
• Supine sleeping position — gravity pulls the tongue and soft palate posteriorly, worsening obstruction in many individuals

Diagnosis of OSAH involves a combination of clinical evaluation and objective sleep testing.

Clinical assessment typically begins with a thorough sleep history, including questions about snoring, witnessed apneas, daytime sleepiness, sleep duration and quality, and associated risk factors. Clinicians often use validated screening instruments such as the STOP-BANG questionnaire, the Epworth Sleepiness Scale (ESS), and the Berlin Questionnaire to stratify risk. A physical examination assesses body mass index, neck circumference, oropharyngeal anatomy (Mallampati score), nasal patency, and craniofacial features.

Polysomnography (PSG) — an overnight sleep study conducted in a sleep laboratory — remains the gold standard for diagnosis. PSG simultaneously records:

• Electroencephalography (EEG) — brain wave activity to determine sleep stages and arousals
• Electrooculography (EOG) — eye movements
• Electromyography (EMG) — muscle activity
• Airflow sensors (nasal pressure transducer and oronasal thermistor)
• Respiratory effort (thoracic and abdominal belts)
• Pulse oximetry — blood oxygen saturation
• Electrocardiography (ECG) — heart rhythm
• Body position sensors

The AHI derived from PSG determines both the presence and severity of the disorder. The study also identifies the predominance of obstructive versus central events, the relationship between events and sleep stage or body position, the degree of oxygen desaturation, and sleep architecture disruption.

Home sleep apnea testing (HSAT) has become an increasingly accepted alternative for adults with a high pre-test probability of moderate-to-severe OSAH and without significant comorbidities. HSAT devices are more limited — they typically measure airflow, respiratory effort, and oxygen saturation without EEG — and tend to underestimate AHI because they cannot distinguish sleep from wakefulness. A negative or inconclusive HSAT in a patient with high clinical suspicion should prompt in-laboratory PSG.

Per DSM-5-TR diagnostic criteria, the disorder requires either: (1) at least five obstructive apneas or hypopneas per hour with evidence of nocturnal breathing disturbance (snoring, snorting, gasping) or daytime sleepiness, fatigue, or unrefreshing sleep not better explained by another condition; or (2) at least 15 obstructive apneas and/or hypopneas per hour regardless of accompanying symptoms.

Treatment for obstructive sleep apnea hypopnea is tailored to severity, underlying pathophysiology, individual anatomy, and patient preference. The goals of treatment are to eliminate apneic events, normalize oxygen levels, restore sleep continuity, and resolve symptoms.

Continuous Positive Airway Pressure (CPAP)

CPAP is the first-line treatment for moderate-to-severe OSAH. A bedside device delivers a constant stream of pressurized air through a mask worn over the nose, mouth, or both, pneumatically splinting the airway open and preventing collapse. When used consistently, CPAP effectively eliminates obstructive events, normalizes oxygen saturation, reduces daytime sleepiness, improves cognitive function, lowers blood pressure, and reduces cardiovascular risk. The primary challenge with CPAP is adherence — research consistently shows that 30–50% of prescribed users do not meet the minimum adherence threshold of four hours per night on 70% of nights. Strategies to improve adherence include proper mask fitting, heated humidification, pressure ramp features, and behavioral support.

Auto-titrating PAP (APAP) and bilevel PAP (BiPAP) devices offer alternatives for patients who cannot tolerate fixed CPAP pressure.

Oral Appliances (Mandibular Advancement Devices)

Custom-fitted oral appliances that advance the mandible forward to enlarge the retroglossal airway space are recommended for patients with mild-to-moderate OSAH or for those who cannot tolerate CPAP. While generally less effective than CPAP at reducing AHI, oral appliances often achieve better adherence, and their effectiveness in real-world use can be comparable. These devices should be fabricated and managed by a dentist trained in dental sleep medicine.

Surgical Interventions

• Uvulopalatopharyngoplasty (UPPP) — removal or remodeling of excess tissue in the soft palate, uvula, and pharynx. Efficacy varies widely and is best for selected patients with specific anatomical findings.
• Maxillomandibular advancement (MMA) — surgically advancing both the upper and lower jaws to expand the skeletal framework of the airway. MMA has the highest success rates among surgical options (often 85–100% in selected patients) and is typically reserved for severe cases or craniofacial deficiency.
• Hypoglossal nerve stimulation — an implanted device that stimulates the nerve controlling the tongue, advancing it forward during inspiration. FDA-approved for moderate-to-severe OSAH in patients who cannot use CPAP, with research demonstrating significant AHI reductions and sustained efficacy over multiple years.
• Tonsillectomy and adenoidectomy — particularly effective in children with OSAH and in adults with significant tonsillar hypertrophy.

Weight Management

For individuals with overweight or obesity, weight loss is a critical component of treatment. A 10–15% reduction in body weight can produce substantial reductions in AHI, and in some cases can resolve OSAH entirely. Bariatric surgery in individuals with severe obesity has demonstrated dramatic improvements in sleep apnea severity, though OSAH often persists to some degree and ongoing monitoring is necessary.

Positional Therapy

For individuals whose OSAH is significantly worse in the supine position (positional OSAH), devices that encourage side sleeping — such as positional belts, specialized pillows, or vibrotactile feedback devices — can meaningfully reduce AHI.

Behavioral and Lifestyle Modifications

• Avoidance of alcohol and sedatives, especially in the hours before sleep
• Smoking cessation
• Treatment of nasal congestion or allergies to improve nasal airflow
• Maintenance of regular sleep schedules and adequate sleep duration

Untreated obstructive sleep apnea hypopnea carries significant long-term health consequences. The intermittent hypoxia, sleep fragmentation, intrathoracic pressure swings, and sympathetic nervous system activation associated with repeated apneic events place substantial stress on multiple organ systems.

Cardiovascular consequences are among the most well-documented. Untreated moderate-to-severe OSAH is independently associated with:

• Systemic hypertension — OSAH is the most common identifiable cause of resistant hypertension
• Atrial fibrillation and other cardiac arrhythmias
• Heart failure — both systolic and diastolic
• Coronary artery disease and stroke
• Pulmonary hypertension

Metabolic consequences include insulin resistance, glucose intolerance, metabolic syndrome, and an elevated risk of type 2 diabetes, independent of obesity.

Neurocognitive consequences are clinically significant. Chronic sleep fragmentation and intermittent hypoxia impair attention, vigilance, executive function, and memory consolidation. Research suggests that some of these cognitive deficits are at least partially reversible with effective treatment, though long-standing severe OSAH may produce structural brain changes that are less amenable to recovery.

Accident risk is substantially elevated. Individuals with untreated OSAH have a two- to seven-fold increased risk of motor vehicle accidents compared to the general population. This risk normalizes with effective treatment.

With consistent, effective treatment — particularly with CPAP adherence or successful surgical intervention — the prognosis for OSAH is generally favorable. Daytime sleepiness typically improves within days to weeks. Blood pressure reductions are observable within weeks to months. Cognitive improvements often emerge over weeks to months of consistent treatment, though the degree of recovery depends on severity and duration of the untreated disorder. Quality of life and mood improve substantially in most treated individuals.

It is important to understand that OSAH is typically a chronic condition. Anatomical and physiological predisposing factors persist, and treatment must generally be maintained long-term unless a definitive anatomical correction is achieved (such as significant weight loss or successful maxillomandibular advancement surgery). Periodic reassessment is recommended, particularly if weight changes, symptoms recur, or new health conditions develop.

Obstructive sleep apnea hypopnea has a complex bidirectional relationship with numerous medical and psychiatric conditions.

Psychiatric comorbidities:

• Major depressive disorder — the relationship between OSAH and depression is robust. Research estimates that 20–40% of individuals with OSAH meet criteria for clinically significant depressive symptoms. Sleep fragmentation, chronic fatigue, and the neurobiological effects of intermittent hypoxia all contribute. Importantly, some depressive symptoms attributed to mood disorders may improve substantially with OSAH treatment, underscoring the importance of screening for sleep-disordered breathing in patients presenting with depression.
• Anxiety disorders — elevated rates of generalized anxiety, panic symptoms, and health-related anxiety are observed in OSAH populations
• Cognitive disorders — emerging research links untreated OSAH to an increased risk of mild cognitive impairment and dementia, potentially through mechanisms involving chronic hypoxia, sleep-dependent amyloid clearance disruption, and vascular injury
• Insomnia disorder — co-occurring insomnia and OSAH (sometimes called COMISA — comorbid insomnia and sleep apnea) is common, affecting an estimated 30–50% of OSAH patients. The presence of both conditions worsens outcomes and complicates treatment.
• PTSD — elevated rates of OSAH are observed in individuals with post-traumatic stress disorder, and untreated OSAH can exacerbate nightmares and sleep disruption

Medical comorbidities:

• Hypertension, heart failure, atrial fibrillation, and stroke
• Type 2 diabetes and metabolic syndrome
• Gastroesophageal reflux disease (GERD) — the negative intrathoracic pressures generated during obstructive events promote reflux
• Obesity hypoventilation syndrome — a related condition in which severe obesity leads to chronic daytime hypoventilation, often coexisting with OSAH
• Central sleep apnea — some patients demonstrate both obstructive and central events, sometimes emerging or worsening after CPAP initiation (treatment-emergent central sleep apnea)

Given these extensive comorbidities, identification and treatment of OSAH has implications far beyond sleep quality — it is a systemic health condition with broad clinical significance.

Evaluation for obstructive sleep apnea hypopnea should be pursued if you or someone you know experiences any of the following patterns:

• Loud, habitual snoring — especially if a bed partner has observed episodes of breathing cessation, gasping, or choking during sleep
• Excessive daytime sleepiness that persists despite adequate time in bed — particularly if it affects driving safety, work performance, or quality of life
• Morning headaches that occur regularly and resolve within hours of waking
• Difficulty concentrating, memory problems, or cognitive complaints that are new, worsening, or unexplained by other conditions
• Treatment-resistant hypertension — if blood pressure remains poorly controlled despite multiple medications, OSAH should be investigated
• Depressive or anxiety symptoms that have not fully responded to standard treatment — undiagnosed OSAH may be contributing
• Frequent nighttime awakenings or nocturia without clear urological cause

The first step is typically a conversation with a primary care provider, who can conduct an initial risk assessment and refer for sleep testing. Board-certified sleep medicine physicians have specialized expertise in diagnosing and managing OSAH and related sleep disorders.

Urgent evaluation is warranted if you are experiencing extreme daytime sleepiness that poses a safety risk — such as nodding off while driving or operating machinery — or if a bed partner observes prolonged periods of breathing cessation during sleep.

If you are already diagnosed with OSAH and are struggling with CPAP adherence, experiencing persistent symptoms despite treatment, or have developed new symptoms, follow-up with your sleep medicine provider is important. Treatment adjustments, alternative therapies, and management of comorbid conditions can substantially improve outcomes.

This article is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. If you have concerns about your sleep or breathing, consult a qualified healthcare professional for evaluation.